Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo

Breast cancers (BrCas) that overexpress oncogenic tyrosine kinase receptor HER2 are treated with HER2-targeting antibodies (such as trastuzumab) or small-molecule kinase inhibitors (such as lapatinib). However, most patients with metastatic HER2(+) BrCa have intrinsic resistance and nearly all event...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xiaokai, Sharko, Amanda C., McDermott, Martina S. J., Schools, Gary P., Chumanevich, Alexander, Ji, Hao, Li, Jing, Zhang, Li, Mack, Zachary T., Sikirzhytski, Vitali, Shtutman, Michael, Ivers, Laura, O’Donovan, Norma, Crown, John, Győrffy, Balázs, Chen, Mengqian, Roninson, Igor B., Broude, Eugenia V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371674/
https://www.ncbi.nlm.nih.gov/pubmed/35914167
http://dx.doi.org/10.1073/pnas.2201073119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371674/
https://www.ncbi.nlm.nih.gov/pubmed/35914167
http://dx.doi.org/10.1073/pnas.2201073119

Ejemplares similares